以浙江麒正药业有限公司研制的磷酸芦可替尼片（规格：20 mg）为受试制剂，持证商为Novartis Europharm Limited的磷酸芦可替尼片（商品名：Jakavi，规格：20 mg）为参比制剂，考察两制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性和耐受性。

开始日期2024-07-16

申办/合作机构

浙江麒正药业有限公司

CTR20242161 / Recruiting临床1期

随机、盲法、安慰剂对照、剂量递增、静脉滴注布罗佐喷钠在健康志愿者中的安全性、耐受性及药代动力学特性临床试验

评估健康志愿者静脉滴注布罗佐喷钠的耐受性、安全性及药代动力学特性。

开始日期2024-06-26

申办/合作机构

杭州澳亚生物技术股份有限公司

[+1]

CTR20234214 / CompletedN/A

浙江麒正药业有限公司提供的恩替卡韦片与持证商为中美上海施贵宝制药有限公司的恩替卡韦片（商品名：博路定®）在中国健康受试者中进行的随机、开放、单剂量、两周期、双交叉、空腹状态下的生物等效性研究

以浙江麒正药业有限公司提供的恩替卡韦片（规格：0.5 mg）为受试制剂，以持证商为中美上海施贵宝制药有限公司的恩替卡韦片（商品名：博路定®，规格：0.5 mg）为参比制剂，考察两制剂在空腹状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性；同时评价两种制剂在健康人体中的安全性和耐受性。

开始日期2024-04-16

申办/合作机构

浙江麒正药业有限公司

100 项与浙江奥翔药业股份有限公司相关的临床结果

登录后查看更多信息

0 项与浙江奥翔药业股份有限公司相关的专利（医药）

登录后查看更多信息

项与浙江奥翔药业股份有限公司相关的文献（医药）

2024-08-21·Crystal Growth & Design

Exploring the Structural Landscape for a Thrombopoietin Receptor Agonist Avatrombopag Maleate: An Innovative Trihydrate Forms with Improved Solubility Found

作者: Liu, Jiyong ; Shi, Dier ; Yu, Kaxi ; Chen, Linshen ; Hu, Xiurong ; Liu, Shuna ; Dai, Chunguang ; Zheng, Zhiguo

Avatrombopag maleate (AVAT), a second-generation oral thrombopoietin (TPO) receptor agonist, is currently in development for the therapeutic management of thrombocytopenia.The present study introduces a novel comparative anal. that elucidates the intricate relationship between the crystallog. structures and the diverse physicochem. properties inherent to the complex polymorphic forms of the Avatrombopag (AVA) maleic salt.Seven solid-state forms, including two polymorphic forms (AVAT-B, AVAT-C), a new trihydrate (AVAT-3H), and four solvates (AVAT-A, AVAT-dimethyl sulfoxide (AVAT-DMSO), AVAT-dimethylformamide (AVAT-DMF), and AVAT-tetrahydrofuran (AVAT-THF)), were synthesized and analyzed in detail.Although the powder diffraction patterns for polymorphs AVAT-A, AVAT-B, and AVAT-C have been previously reported, our study marks the inaugural report of their crystallog. structures.Trihydrate and three new solvates were initially identified and subjected to a comprehensive characterization through thermal anal., X-ray diffraction, etc.Thermal stability and transformation in aqueous solutions for different forms were conducted.Surprisingly, it was found that all five other solid forms except AVAT-B would be transformed to AVAT-3H when suspended in aqueous solutionAll solvates retained their original framework structure after the removal of part of the solvent and could not lose all solvents until decompositionAVAT trihydrate did not lose water upon storage under ambient conditions.Furthermore, the solubility profiles of AVAT-B, AVAT-C, and AVAT-3H were meticulously determinedBy integrating the distinct mol. conformations with the resp. intermol. and intramol. interactions as well as the packing arrangements, we were able to elucidate the underlying factors influencing their phase behavior.The insights gained from this anal. were instrumental in simulating crystal growth, thereby facilitating a comprehensive understanding of the specific interactions that govern the phase behavior of these compounds

2024-01-01·European Journal of Pharmaceutical Sciences

A first-in-human study of Brozopentyl Sodium, following single and multiple ascending intravenous infusion in Chinese healthy volunteers

Article

作者: Li, Yun-Feng ; Xie, Ran ; Cui, Yi-Min ; Sheng, Xiao-Yan ; Zhao, Xia ; Zheng, Zhi-Guo ; Jia, Bo ; Wei, Lu-Hua

BACKGROUNDBrozopentyl Sodium (BZP), a novel agent for ischemic stroke, has shown promising results in preclinical pharmacological studies, prompting the initiation of the first-in-human investigation.PURPOSEThis study aimed to assess the safety, tolerability, and pharmacokinetic (PK) characteristics of BZP in Chinese healthy volunteers.METHODSThe study consisted of two parts. Part I was a single-center, randomized, single-blinded, placebo-controlled, single-ascending study with six BZP dose cohorts (SAD: 25, 50, 100, 200, 300, and 400 mg). Part II was a single-center, randomized, single-blinded, placebo-controlled, multi-dose- and dose-elevated study with three BZP dose cohorts (MAD: 50, 100, and 200 mg). Doses were administered once daily on days 1 and 7 and twice daily on days 2-6. The PK properties of BZP and its bioactive metabolites, BNBP, were assessed. Safety and tolerability evaluations were also conducted.RESULTSIn the SAD study, BZP reached peak plasma concentrations (T_max) at the end of administration, with median T_max values ranging from 1 to 1.03 h, while BNBP reached T_max between 1.25 to 1.38 h. The terminal half-lives (T_1/2) were approximately 8 h for BZP and 15 h for BNBP. In the MAD study, steady-state plasma concentrations of BZP were reached by day 5. There was minimal accumulation of both BZP and BNBP after 7 days of administration. The area under the plasma concentration-time curve from 0 to time of the last measurable concentration (AUC_0-t) and maximum plasma drug concentration (C_max) showed dose-proportional increases for BZP but not for BNBP in both study parts. Single and multiple doses of BZP demonstrated a good safety profile and were well-tolerated.CONCLUSIONBZP displayed safety, good tolerability and predictable PK characteristics following both single and multiple ascending intravenous administrations. These findings provide a basis for further clinical development of BZP for ischemic stroke patients.

2018-09-01·Journal of Pharmaceutical and Biomedical Analysis3区 · 医学

Quantitation of polymorphic impurity in entecavir polymorphic mixtures using powder X-ray diffractometry and Raman spectroscopy

3区 · 医学

Article

作者: Kang, Yanlei ; Shao, Zhanying ; Wang, Qiang ; Hu, Xiurong ; Yu, Dongdong

Entecavir was used for the treatment of chronic hepatitis B through inhibiting hepatitis B virus. The anhydrous form of entecavir (ENT-A) often appeared as impurity polymorph in the manufacturing process of entecavir monohydrate (ENT-H) such as granulation, drying and compression. Since different crystal forms might affect drug bioavailability and therapeutic effect, it was vital to control the ENT-A content of the drug product. The work aimed to develop useful methods to assess ENT-A weight percentage in ENT-H. Powder X-ray diffractometry (PXRD) and Raman spectrometric methods were applied. Binary mixtures with different ratios of pure ENT-H and pure ENT-A were scanned using PXRD and Raman to obtain spectra. Then peak heights and peak areas versus weight percentage were used to construct calibration curves. The best linear regression analysis data for PXRD and Raman method were found to be R² = 0.9923 and R² = 0.9953, in the weight ratio range of 2.1-20.2% w/w% of ENT-A in binary mixtures. Limit of detection (LOD) of ENT-A was 0.38% and limit of quantitation (LOQ) was 1.15% for PXRD method. LOD and LOQ for Raman method were 0.48% and 1.16%. The results showed that PXRD and Raman methods: both were precise and accurate, and could be used for measurement of ENT-A content in the selected weight percentage range. Partial least squares (PLS) algorithm with four data pre-processing methods: including multiplicative scatter correlation (MSC), standard normal variate (SNV), first and second derivatives were applied and evaluated using prediction errors. The best performance of PLS was R² = 0.9958 with RMSEC (0.44%) and RMSEP (0.65%). Multivariate analysis for Raman spectra showed similar good results with univariate analysis, and would be an advantageous method when there were overlapped peaks in the spectra. In summary, the proposed PXRD and Raman method could be developed for the quality control of ENT-H. And Raman was a more promising method in industrial practice due to its slightly better precision, accuracy and time-saving advantage.

项与浙江奥翔药业股份有限公司相关的新闻（医药）

2024-03-17

·蒲公英Ouryao

药企高管变动→3位副总、1位董事长辞职

来源：企业公告整理：wangxinglai2004近日，又有4家上市药企发布了高层管理人员变动信息，分别为龙安徽墨药副总经理辞职、奥翔药业副总经理辞职、特一药业副总经理辞职和长药控股董事长辞职。 01 安徽墨药副总经理辞职近日，本公司董事会于收到副总经理郑卫勇先生递交的辞职报告，因个人原因，主动申请辞去公司副总经理的职务，自2024 年3月5日起辞职生效。上述辞职人员持有公司股份0股，占公司股本的0%。不是失信联合惩戒对象，辞职后不再担任公司其它职务。 02 奥翔药业副总经理辞职近日，浙江奥翔药业股份有限公司董事会于收到公司现任副总经理宋继国先生的书面辞职报告。宋继国先生因个人原因申请辞去公司副总经理职务，辞职后将不再担任公司任何职务，其辞职报告自送达公司董事会之日起生效。公司董事会对宋继国先生在任职期间所做的贡献表示衷心感谢！ 03 特一药业副总经理辞职特一药业集团股份有限公司董事会于近日收到公司副总经理张清民先生的书面辞职报告，张清民先生因年龄原因辞去公司副总经理职务。根据《公司法》及《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》的相关规定，张清民先生的辞职报告自送达董事会之日起生效。辞职后，张清民先生将不在公司担任任何职务。截至本公告日，张清民先生未持有公司股票；张清民先生持有公司2021年股票期权激励计划已获授但尚未行权的股票期权98,000份，将由公司根据《2021年股票期权激励计划》的规定予以注销。 04 长药控股董事长辞职2024年3月15日，长江医药控股股份有限公司发布公告，公司收到董事长李金凤女士提交的书面《辞呈》。因个人原因，李金凤女士辞去公司第五届董事会董事长、董事职务，辞职后不在公司及下属公司担任任何职务。截至本公告披露之日，李金凤女士未持有公司股票。

高管变更

2023-10-11

·药研发

【药研发1012】成都惠泰吸入多肽新药获批临床 | 信立泰NRG1融合抗体心衰Ib期临床积极...

「本文共：15条资讯，阅读时长约：3分钟」今‍日‍头条成都惠泰吸入多肽新药获批临床。成都惠泰生物自研11aa多肽1类化药吸入用HTPEP-001获国家药监局临床许可，拟开发用于进行性纤维化性间质性肺疾病（PF-ILD），包括特发性肺纤维化（IPF）、结缔组织病相关间质性肺疾病（CTD-ILD）、尘肺、病毒感染及其他病因引起的一类伴肺纤维化进展的间质性肺疾病。HTPEP-001通过特异性阻断CD36与TSP-1的相互作用，从而抑制活性TGF-β1解离，达到对多条促纤维化信号通路的调控。‍‍‍国‍‍‍‍‍‍‍‍‍内‍‍‍‍药‍‍讯‍‍‍‍1.德琪引进XPO1抑制剂新适应症报产。德琪医药口服选择性核输出蛋白（XPO1）抑制剂塞利尼索片（商品名：希维奥）新适应症上市申请获CDE受理，推测适应症为“用于治疗复发/难治性弥漫性大B细胞淋巴瘤（R/R DLBCL）患者”。塞利尼索是首款获FDA批准的口服XPO1抑制剂，由Karyopharm公司研发，德琪医药拥有该新药在包括大中华区、韩国等多个亚太市场的独家权利。2.科伦博泰TROP2-ADC启动肺癌国际Ⅲ期临床。科伦博泰与默沙东开发的Trop2 ADC新药SKB264（MK-2870）在Clinicaltrials.gov网站上注册一项国际Ⅲ期临床，拟评估用于治疗EGFR等突变非小细胞肺癌的有效性与安全性。该项研究计划入组556例患者，预计2027年5月初步完成。SKB264是由科伦博泰采用其专有毒素-连接子策略（Kthiol设计策略）研发的一款创新ADC，默沙东拥有该新药在中国以外区域开发、生产和商业化授权。3.信立泰NRG1融合抗体心衰Ib期临床积极。信立泰旗下美国子公司Salubris在HFSA2023年会上公布其NRG-1融合抗体JK07治疗射血分数降低型心衰（HFrEF）患者的美国Ib期临床积极数据。单次给药180天后，JK07（0.03mg/kg、0.09mg/kg和0.27mg/kg）组患者LVEF（左室射血分数）平均改善7%、49%和31%；JK07总体耐受性良好，大多数不良事件为轻度至中度。JK07将在II期临床中进一步评估用于HFrEF和HFpEF（射血分数保留的心衰）患者的疗效和安全性。4.杭州高诚TNFR2单抗获批实体瘤临床。高诚生物潜在“first-in-class”激动型 TNFR2抗体HFB200301注射液获国家药监局临床试验默示许可，拟开发用于治疗晚期或转移性实体瘤。HFB200301可通过选择性地与TNFR2结合并诱导CD4 T细胞和CD8 T细胞以及NK细胞的活化。目前，该新药正在美国和欧洲开展Ⅰ期临床试验（NCT05238883），评估单药和与PD-1免疫检查点抑制剂Tislelizumab（替雷利珠单抗）联合用药的安全性与有效性。5.先声引进安缔康一款抗流感新药。先声药业与安谛康生物就后者临床后期聚合酶酸性蛋白（PA）抑制剂ADC189达成合作协议，先声药业将获得ADC189用于流行性感冒（流感）适应症在中国的独家商业化权益。ADC189可通过抑制CAP帽状-依赖型核酸内切酶（CEN）直接抑制流感病毒的复制，对抗甲型流感和乙型流感病毒。目前，该新药已处于III期临床开发阶段。‍‍‍‍国‍‍‍‍‍‍‍‍‍‍际‍‍‍‍药‍讯‍‍1.默沙东K药早期肺癌Ⅲ期临床成功。默沙东PD-1抑制剂Keytruda用于可切除II-IIIB期非小细胞肺癌（NSCLC）的Ⅲ期临床（KEYNOTE-671）达到主要终点。此前，在中位随访25.2个月时，Keytruda联合化疗新辅助治疗，并在术后单药辅助治疗将疾病复发、进展或死亡风险降低42%（HR=0.58 ;p=＜0.00001）。最新数据显示，Keytruda新辅助/辅助治疗方案显著提高患者的总生存期（OS）。目前，Keytruda用于上述适应症的sBLA申请正接受FDA审查。2.司美格鲁肽慢性肾病Ⅲ期临床积极。诺和诺德GLP-1激动剂司美格鲁肽辅助治疗合并肾功能不全2型糖尿病和慢性肾病的Ⅲ期临床FLOW达到提前结束试验的预定指标。IDMC评估的中期数据显示，该产品疗效达到了特定的预设标准，建议提前终止该项临床。详细数据预计2024年上半年公布。据悉，诺和诺德也在探索该新药用于NASH、阿尔茨海默症、外周动脉疾病（PAD）等适应症。3.DHODH阻断剂多发性硬化Ⅱ期临床积极。Immunic公司DHODH阻断剂vidofludimus calcium（IMU-838）治疗进展性多发性硬化（PMS）患者的Ⅱ期CALLIPER试验结果积极。第24周时，与安慰剂组相比，IMU-838治疗组患者血清神经丝蛋白轻链（NfL）标志物较基线降低6.7%（p=0.01），而安慰剂组则升高15.8%；两组患者胶质纤维酸性蛋白（GFAP）水平分别增加3.7%和4.4%。显示该新药具原已知抗炎症作用外的神经保护潜力。Immunic预计在2025年4月获得该试验的顶线数据。4.AOCs药物治疗强直性肌营养不良长期疗效积极。Avidity Biosciences公司抗体偶联寡核苷酸（AOCs）药物AOC 1001治疗1型强直性肌营养不良（DM1）的Ⅰ/Ⅱ期临床MARINA-OLE研究结果积极。此前初步数据显示，在单剂1 mg/kg或双剂2 mg/kg的AOC 1001注射后，患者致病DMPK mRNA水平平均下降45%。最新数据显示，AOC 1001能改善包括手部握力、肌力和患者报告结果等其他功能性指标；且药物长期耐受性良好。5.S1P受体1调节剂结肠炎Ⅱ期临床成功。Ventyx公司口服鞘氨醇1-磷酸（S1P）受体1调节剂VTX002治疗中重度活动性溃疡性结肠炎（UC）的Ⅱ期临床达到主要终点。VTX002通过与S1P受体1结合，阻止淋巴细胞离开淋巴结，导致血液循环中加剧炎症的淋巴细胞数量减少。数据显示，与安慰剂相比，VTX002（60mg和30mg）治疗组患者第13周时达到临床缓解的患者比例更高（28%和24%，vs11%）。临床中未观察到治疗相关严重不良事件。6.Fc-FGF21融合蛋白NASH临床未达主要终点。Akero公司Fc-FGF21融合蛋白Efruxifermin（EFX）治疗代偿性肝硬化（F4）非酒精性脂肪性肝炎（NASH）的IIb期SYMMETRY研究未达到主要终点。第36周时，Efruxifermin（28mg和50mg）治疗组和安慰剂组实现肝纤维化改善≥1级且NASH没有恶化的患者比例分别为22%、24%和14%，不具有统计学意义。两组获得NASH缓解的比例分别为63%、60%和26%，具有统计学意义；药物总体耐受性良好。‍‍‍‍‍‍‍‍‍医‍‍‍‍‍‍药‍‍‍‍‍‍‍‍‍‍‍‍‍热‍‍‍‍‍‍‍点‍。1.东南大学附属中大医院妇产科专科联盟启动。10月7日，东南大学附属中大医院医联体妇产科专科联盟启动仪式暨联盟科主任会议在南京举行。中大医院医联体妇产专科联盟的成立，旨在通过资源共享、技术协作、培训交流等方式，推动63家医院成员单位之间的紧密合作，实现医疗资源的优化配置和医疗水平的共同提升，尤其是提高妇产科疾病的疑难诊疗水平，为患者提供更加全面、便捷的医疗服务。2.济南将新添一家三级综合医院。10月8日，济南医院迁建项目建设工程规划许可批前公示，医院将迁建至华山片区，建设成三级综合医院。根据公示，济南医院迁建至济南市历城区华山片区小清河北路以北，听水路以南，云芝北路以东，洪园路以西。项目用地面积57452平方米，总建筑面积（含保温层）117568平方米，地上建筑面积71600平方米，地下建筑面积45968平方米。3.北京胸科医院精神心理科建立。10月10日，北京胸科医院精神心理科正式开科诊疗。北京胸科医院精神心理科由精神科医师、心理治疗师、国家心理咨询师和心理测查师，以及护理人员组成，设立心理门诊、心理测查室、物理治疗室和“双心”病房，主要开展抑郁、焦虑、睡眠障碍与儿童青少年和老年期心理障碍等诊疗。‍‍‍‍‍‍‍评‍‍‍‍‍审‍‍‍‍动‍‍态‍‍‍‍‍‍‍ 1. CDE新药受理情况（10月11日) 2. FDA新药获批情况（北美10月09日）股市资讯上个交易日 A 股医药板块 +0.97%涨幅前三跌幅前三科源制药+20.00% ST 交昂 -3.72%神奇制药+10.05% 华兰疫苗 -3.48%奥翔药业+10.04% *ST太安 -2.87%【国药现代】注射用头孢唑林钠收到国家药品监督管理局核准签发的药品补充申请批准通知书，通过仿制药质量和疗效一致性评价，适用于治疗敏感细菌所致的呼吸道感染、尿路感染等感染性疾病。【津药药业】甘氨酰谷氨酰胺、甘氨酰酪氨酸收到国家药品监督管理局核准签发的化学原料药上市申请批准通知书。【黄山胶囊]2023前三季度，公司实现营业收入9982.47万元，比上年同期增长6.59%;实现归属于上市公司股东的净利润1714.22万元，比上年同期增长3.37%;实现归属于上市公司股东的扣除非经常性损益的净利润1628.29万元，比上年同期增长13.01%。- The End -戳“阅读原文”，了解更多医药研发及股市资讯。

抗体药物偶联物临床3期申请上市临床2期临床1期

2023-09-06

·GlobeNewswire-Health Care

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from the United States Patent and Trademark Office (USPTO), No. 11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast), entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis.” The invention claims treating non-alcohol fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast. The base claims of the patent will be valid through 2039, excluding any patent term adjustments or extensions which may provide additional protection. The Company has also filed corresponding patent applications in Canada, Europe, China and Japan. The company previously disclosed that Repirinast, in a widely used STAM™ mouse model of NASH from SMC Laboratories (Japan): Reduced hepatic fibrosis by 57% compared to vehicle (p < 0.0001);Reduced the NAFLD score, a composite histopathological measure of inflammation, steatosis and ballooning, by 31% compared to vehicle (3.125 vs 4.5 points, p = 0.059);In the same model, telmisartan, a positive control and the standard of care for NASH, reduced fibrosis by 27% (p = 0.014) Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction (UUO) mouse model. Because patients with NAFLD have a two-fold increased risk of CKD, even when controlling for other comorbidities such as obesity, type 2 diabetes mellitus and insulin resistance, Repirinast is a strong candidate for both indications. Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing and formulations, and for new composition of matter patents based on novel salt forms. “This is the first patent received from the USPTO by Algernon for one of its drugs being investigated under its innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “The Company’s global intellectual property suite now includes three granted patents in additional to 21 patents pending.” About NP-251 (Repirinast) Repirinast was originally developed by Mitsubishi Tanabe Pharma (“Mitsubishi”) and was sold and marketed in Japan under the brand name Romet™ for the treatment of Asthma. Romet™ was marketed for over 25 years in Japan. Mitsubishi discontinued manufacturing and sales of the drug in 2013. Accordingly, Algernon has retained Zhejiang Ausun Pharmaceutical in Zhejiang, China to manufacture a cGMP Repirinast supply. Mast cells are recruited to sites of cellular damage, and degranulation of mast cells leads to release of a myriad of proinflammatory chemical mediators which lead to tissue damage in a self-propagating cascade. NP-251 binds to receptors on mast cells and prevents their degranulation, which the Company believes could help prevent fibrosis in multiple organ classes including the kidneys. About Algernon Pharmaceuticals Algernon Pharmaceuticals is a Canadian clinical stage drug development and repurposing company investigating multiple drugs for unmet global medical needs. Algernon Pharmaceuticals has active research programs for IPF with chronic cough, and chronic kidney disease, and is the parent company of a newly created private subsidiary called Algernon NeuroScience, that is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury. CONTACT INFORMATION Christopher J. MoreauCEOAlgernon Pharmaceuticals Inc.604.398.4175 ext 701 info@algernonpharmaceuticals.cominvestors@algernonpharmaceuticals.comwww.algernonpharmaceuticals.com. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

上市批准临床结果专利到期

100 项与浙江奥翔药业股份有限公司相关的药物交易

登录后查看更多信息

100 项与浙江奥翔药业股份有限公司相关的转化医学

登录后查看更多信息